[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the International Agency for Research on Cancer (IARC), worldwide one in ...

There are several different types of anti estrogen supplements available, including aromatase inhibitors, selective estrogen receptor modulators (SERMs), and estrogen blockers. Each of these ...

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers recurring. The decision by the National Institute for Health and Care ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

We played a leading role in clinical trials that demonstrated the effectiveness of aromatase inhibitors in breast cancer, and in identifying and validating biomarkers to determine who could benefit ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...